Drug Trial Radar · NCT03353753
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
Last checked: Nov 19, 2026Latest source record: Nov 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Feb 27, 2018
Primary completion
May 31, 2019
Study completion May 11, 2022
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo
Conditions
- Gastrointestinal Stromal Tumors
Interventions
DCC-2618Drug
Oral KIT/PDGFRA kinase inhibitor
Placebo Oral TabletDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From date of randomization to the earliest date of disease progression or death from any cause [through database cutoff 31-May-2019 (up to approximately 15 months)].
Locations
35 sites in 13 countries. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
University of Southern California - Norris
Los Angeles, California
UCLA
Los Angeles, California
Stanford
Stanford, California
Mayo Clinic - Jacksonville
Jacksonville, Florida
Georgia Cancer Specialists
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Columbia
New York, New York
MSKCC
New York, New York
Oregon Health & Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Alfred University
Melbourne, Australia
University Hospital Leuven
Leuven, Belgium
Princess Margaret Hospital
Toronto, Canada
Cross Cancer Center
Edmonton, Alberta, Canada
Helsinki University Central Hospital
Helsinki, Finland
Institut Bergonié
Bordeaux, France
Le Centre Léon Bérard
Lyon, France
Gustave-Roussy
Villejuif, France
Sarcoma Center Brandenburg
Brandenburg, Germany
University Hospital Essen
Essen, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
Istituto Nazionale dei Tumori
Milan, Italy
Università Campus Bio-Medico di Roma
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
Maria Sklodowska-Curie Memorial Cancer Center
Warsaw, Poland
NCC
Singapore, Singapore
Vall d'Hebron
Barcelona, Spain
Hospitalario Universitario Virgen del Rocío
Seville, Spain
Royal Marsden
London, United Kingdom
University of Sheffield
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.